Comparative Effects of a New Cardioselective Beta‐Blocker Nebivolol and Nifedipine Sustained‐Release on 24‐Hour Ambulatory Blood Pressure and Plasma Lipoproteins

Lacourcière, Yves; Poirier, Luc; Lefèbvre, J; Provencher, Pierre; Arnott, Wendy

doi:10.1002/j.1552-4604.1992.tb05778.x

Cited by 45 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…28 In this study, no effect on serum glucose levels was observed, correlating with similar findings with respect to effects on glucose metabolism in previous studies of nebivolol. [29][30][31][32] Thus, the data in this study may further support the use of nebivolol as an appropriate add-on therapy. 33 The additional BP lowering provided by nebivolol as add-on therapy has the potential to reduce the risks of uncontrolled hypertension, without compromising tolerability.…”

Section: Discussionsupporting

confidence: 55%

Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I–II hypertension

2009

View full text Add to dashboard Cite

This study assessed blood pressure (BP) reductions and response rates following addition of nebivolol to ongoing antihypertensive therapy in patients with uncontrolled stage I-II hypertension despite antihypertensive treatment. Patients with an average sitting diastolic BP (SiDBP) X90 and p109 mm Hg while taking an antihypertensive regimen were included in this double-blind, placebo-controlled, parallel-group study. The primary efficacy end point was reduction from baseline to week 12 in mean trough SiDBP. In total, 669 patients were randomized to once-daily nebivolol 5, 10 or 20 mg or placebo. Addition of nebivolol 5, 10 and 20 mg significantly reduced BP; placebo-subtracted least squares mean reductions in trough SiDBP were À3.3, À3.5 and À4.6 mm Hg, respectively (Po0.001) and À5.7, À3.7 and À6.2 mm Hg in trough sitting systolic BP (SiSBP), respectively (Pp0.015). Adding nebivolol 5-20 mg resulted in significantly more responders (SiDBP o90 or X10 mm Hg reduction; range: 53.0-65.1 vs 41.3% with placebo; Pp0.028) and significantly better control rates (SiSBP/ SiDBP o140/90 mm Hg; range: 41.3-52.7 vs 29.3% with placebo; Pp0.029). Nebivolol was well tolerated; the incidence of adverse events with nebivolol was similar to that with placebo (40.2 vs 38.9%, respectively; P ¼ 0.763). Addition of once-daily nebivolol to ongoing antihypertensive therapy provided significant additional BP reductions and better response rates in patients with uncontrolled hypertension and was well tolerated.

show abstract

Section: Discussionsupporting

confidence: 55%

Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I–II hypertension

2009

View full text Add to dashboard Cite

show abstract

“…Nebivolol 5 mg once daily was also of an equivalent antihypertensive efficacy as the b 1 -adrenergic receptor selective blocker atenolol (which is devoid of intrinsic vasodilator properties) both in hypertensive [18] and in hypertensive/diabetic patients [19]. Nebivolol 5 mg once daily was also demonstrated to be able to reduce clinic and 24-h blood pressure similarly to the calcium-channel blocker nifedipine 20 mg twice daily [20,21]. However, nebivolol was better tolerated than nifedipine.…”

Section: Discussionmentioning

confidence: 88%

Evaluation of the Efficacy and Tolerability of Nebivolol versus Lisinopril in the Treatment of Essential Arterial Hypertension: A Randomized, Multicentre, Double-blind Study

Rosei¹,

Rizzoni²,

Comini³

et al. 2003

Blood Pressure

View full text Add to dashboard Cite

Rosei EA, Rizzoni D, Comini S, Boari G. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Pressure 2003; 12 (Suppl 1): 30-35.The main objective of this study was to compare the anti-hypertensive efficacy and safety of nebivolol (5 mg once daily) and lisinopril (20 mg once daily) given for 12 weeks in patients with mild to moderate essential hypertension. Fourteen centres participated in this randomized, double-blind parallel group study. Sixty-eight patients with uncomplicated mild-to-moderate hypertension were randomized, and sixty-five were eligible for the analysis of efficacy (intention-to-treat). Hypertensive patients were newly diagnosed, or previous antihypertensive therapy was withdrawn at least 1 month before active treatment, and were included in the study if their diastolic blood pressure (DBP) was >95 and <114 mmHg. The age range was 24-65 years. The primary endpoints of the study were: (i) response rate: patients were defined as "normalized" responders if their blood pressure values were <140/90 mmHg, or as "non-normalized" responders if the reduction in blood pressure was 10 mmHg or more, compared with baseline; (ii) changes in sitting blood pressure at the end of the study. The secondary endpoints were: standing blood pressure and sitting or standing heart rate (HR). Results showed that baseline sitting DBP was significantly different between groups. Analysis of covariance of the raw data performed with baseline as covariate demonstrated that the DBP and HR values were significantly lower in the nebivolol group at the 8th week. However, when an analysis of variance for repeated measures was performed, a significant reduction in sitting systolic blood pressure (SBP) (p < 0.0001), DBP (p < 0.0001) and HR (p < 0.0001) was observed throughout the study in both groups. No difference was observed between treatments, although for DBP, a significant interaction between treatment-weeks was observed (p = 0.016). There was also a statistically significant difference in favour of the nebivolol group in the distribution of responders and nonresponders at week 8. Lisinopril and nebivolol were equally well tolerated. In conclusion, nebivolol was slightly more effective, in comparison with lisinopril, in terms of reduction in DBP. This greater efficacy was obtained without any increase in adverse effects, since both treatments were equally well tolerated.

show abstract

“…The response rate -de ned as "normalized responder" if the BP values were <140/90 or "nonnormalized responder" if the reduction of DBP was ¶10 mm Hg compared to baseline -was found to be different between nebivolol [17] and amlodipine [18].…”

Section: Ef Cacy Assessmentmentioning

confidence: 99%

Nebivolol vs Amlodipine as First-line Treatment of Essential Arterial Hypertension in the Elderly

et al. 2002

View full text Add to dashboard Cite

The antihypertensive efficacy of nebivolol and amlodipine and their tolerability were compared in a multicentre, randomized, active-controlled, double-blind parallel-group trial in elderly patients with mild to moderate essential arterial hypertension. One hundred and eighty-four subjects aged > or = 65 years were screened. After a run-in phase of 4 weeks, only 168 of these were randomized with either nebivolol 2.5-5 mg daily (n = 81) or amlodipine 5-10 mg daily (n = 87) over a period of 12 weeks. The response rate to treatment and the changes of sitting diastolic blood pressure (BP) at week 12 were similar between the two groups. A lower sitting systolic BP (SBP) was detected with amlodipine at week 4 (p < 0.05) and at week 8 (p < 0.05). Standing BP showed no changes between the two groups; only SBP was lower with amlodipine at week 8 (p < 0.05). Heart rate was lower at all treatment visits with nebivolol (p < 0.001). The incidence of adverse events was no different between the two groups; however the incidence of headache and ankle oedema was significantly higher with amlodipine (p < 0.05). In elderly subjects with essential hypertension, the antihypertensive efficacy of nebivolol and amlodipine was similar. Both drugs were well tolerated, although amlodipine was accompanied by higher incidence of drug-related adverse events.

show abstract

Comparative Effects of a New Cardioselective Beta‐Blocker Nebivolol and Nifedipine Sustained‐Release on 24‐Hour Ambulatory Blood Pressure and Plasma Lipoproteins

Cited by 45 publications

References 22 publications

Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I–II hypertension

Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I–II hypertension

Evaluation of the Efficacy and Tolerability of Nebivolol versus Lisinopril in the Treatment of Essential Arterial Hypertension: A Randomized, Multicentre, Double-blind Study

Nebivolol vs Amlodipine as First-line Treatment of Essential Arterial Hypertension in the Elderly

Contact Info

Product

Resources

About